#USA #New York #Gross Law Firm #Unicycive Therapeutics #UNCY

Legal Rights Notification for Unicycive Therapeutics Shareholders

On September 18, 2025, The Gross Law Firm issued an important message to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This notification is specifically aimed at individuals who acquired shares during a designated class period, which spans from March 29, 2024, to June 27, 2025. The firm is urging these shareholders to make contact to discuss their rights and explore possible avenues for legal recourse.

Context of the Class Action

The call to action from The Gross Law Firm comes amid allegations that Unicycive Therapeutics misrepresented its operational readiness and the regulatory viability of its new drug applications. According to the complaint, during the class period, the company is accused of issuing materially false statements regarding:

1. Compliance with FDA Manufacturing Standards: Defendants allegedly overstated the company’s capability to meet the FDA's manufacturing compliance requirements.
2. Regulatory Prospects for New Drug Products: Misleading assertions about the regulatory potential of oxylanthanum carbonate, a new drug application by Unicycive.
3. Overall Public Communication: Consequently, public statements made by the company have been characterized as materially misleading at various points in time.

The seriousness of these allegations informs shareholders of the potential risks and impacts associated with their investments in Unicycive.

Action Steps for Shareholders

Shareholders who acquired shares during the specified class period are strongly encouraged to register for participation in this class action. Registration does not require an upfront obligation, nor does it necessitate a commitment to become a lead plaintiff—although those interested in taking on that role must do so by the deadline of October 14, 2025.

The Gross Law Firm will provide enrolled shareholders with a status monitoring service throughout the litigation process, allowing them to stay informed about developments and any actions needed on their part. For those interested, registration can be completed through the provided link or by reaching out to the law firm directly.

About The Gross Law Firm

The Gross Law Firm prides itself on being a prominent player in the space of class action lawsuits, focused on protecting the rights of investors impacted by dishonest business practices. Their commitment revolves around ensuring that companies adhere to ethical standards and provide accurate information to their stakeholders. As they navigate this complex landscape, they seek remedy for investors who may have incurred financial losses due to deceptive actions and misleading communications by the firms they invest in.

For further inquiries or to report your involvement with Unicycive, shareholders can contact The Gross Law Firm based in New York via email at [email protected] or by phone at (646) 453-8903.

In closing, the firm emphasizes that taking part in this action is crucial for shareholders to ensure their voices and rights are represented appropriately in the legal proceedings against Unicycive Therapeutics. The deadline for action is fast approaching, and timely registration is key to safeguarding potential recovery.

Conclusion

As legal proceedings unfold, investors must remain proactive in understanding their rights and options. The Gross Law Firm stands ready to assist Unicycive Therapeutics shareholders in this regard, providing a path toward potential recovery amid the challenges posed by misleading corporate practices. Don't delay; contact the firm before the deadline.